skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Tipifarnib in the treatment of acute myeloid leukemia

(2888) Views  (638) Full article downloads

Authors: Xavier Thomas, Mohamed Elhamri

Published Date January 2007 Volume 2007:1(4) Pages 415 - 424
DOI: http://dx.doi.org/10.2147/BTT.S

Xavier Thomas, Mohamed Elhamri

Hematology, Edouard Herriot Hospital, Lyon, France

Abstract: Farnesyltransferase inhibitors (FTIs) are a new class of biologically active anticancer drugs. The exact anti-tumorigenic mechanism is currently unknown. FTIs inhibit farnesylation of a wide range of target proteins. In preclinical models, tipifarnib (R115777, Zarnestra®), a non-peptidomimetic competitive FTI, showed great potency against leukemic cells. Although it has recently demonstrated clinical responses in adults with refractory and relapsed acute myeloid leukemia (AML), and in older adults with newly diagnosed poor-risk AML, its activity was far less than anticipated. However, it appears that tipifarnib as a single agent may be important in selected groups of patients. Much remains to be learned to optimize such therapy in patients with AML. To this end, trials that combine tipifarnib with cytotoxics are ongoing.

Keywords: tipifarnib, farnesyltransferase inhibitor, acute myeloid leukemia, prognosis, targeted therapy








Readers of this article also read:

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
Targeted therapies in rheumatoid arthritis: Focus on rituximab
Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome
Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS)
Evolving therapies in the treatment of hepatocellular carcinoma
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap)
Therapeutic vaccines for malignant brain tumors
Targeted therapy in melanoma
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed